HYDERGINE LC
Clinical safety rating: caution
Comprehensive clinical and safety monograph for HYDERGINE LC (HYDERGINE LC).
Ergoloid mesylates (dihydroergotoxine) act as a partial agonist/antagonist at dopamine (D1, D2), serotonin (5-HT1, 5-HT2), and alpha-adrenergic receptors. They enhance cerebral metabolism and increase blood flow via vasodilation and neuroprotection.
| Metabolism | Extensively metabolized in the liver via cytochrome P450 (CYP3A4) to multiple inactive metabolites. First-pass effect results in low systemic bioavailability. |
| Excretion | Renal (80% as metabolites, <1% unchanged); biliary/fecal (20%). |
| Half-life | Terminal elimination half-life: 12–15 hours. Clinical context: steady-state achieved in 2–3 days; allows once-daily dosing. |
| Protein binding | ~42% bound to plasma proteins (primarily albumin). |
| Volume of Distribution | Vd: ~120 L (1.7 L/kg for 70 kg). Clinical meaning: extensive tissue distribution. |
| Bioavailability | Oral: 5–10% (extensive first-pass metabolism); sublingual: 25–30%. |
| Onset of Action | Oral: 1–2 hours; sublingual: 15–30 minutes. |
| Duration of Action | Duration: 8–12 hours after single dose. Clinical notes: cognitive effects persist for several hours; chronic therapy required for dementia indication. |
| Molecular Weight | 387.49 Da (dihydroergocristine mesylate component; note Hydergine LC is a mixture of dihydroergocristine, dihydroergocornine, and dihydroergocryptine, with molecular weights ~387-397 Da) |
Oral, 1 mg three times daily. Titrate up to 2 mg three times daily if needed.
| Dosage form | CAPSULE |
| Renal impairment | No specific guidelines; use with caution in severe renal impairment (CrCl <30 mL/min) due to potential accumulation. |
| Liver impairment | Avoid use in severe hepatic impairment (Child-Pugh class C). In moderate impairment (Child-Pugh class B), reduce dose by 50% and monitor. |
| Pediatric use | Safety and efficacy in pediatric patients have not been established; not recommended for use in children. |
| Geriatric use | Initiate at low end of dosing range (1 mg once or twice daily) due to increased sensitivity and risk of orthostatic hypotension; titrate slowly. |
| 1st trimester | Contraindicated due to risk of ergotism and uterotonic effects causing fetal hypoxia. |
| 2nd trimester | Contraindicated; ergot alkaloids may induce uterine contractions and decrease placental blood flow. |
| 3rd trimester | Contraindicated; use near term may cause prolonged uterine contractions and fetal distress. |
Clinical note
Comprehensive clinical and safety monograph for HYDERGINE LC (HYDERGINE LC).
| Placental transfer | Ergot alkaloids cross the placenta; detectable levels in fetal circulation. |
| Breastfeeding | Ergot alkaloids are excreted in breast milk and may cause ergotism in the infant (vomiting, diarrhea, convulsions). Also can reduce milk production. Use is contraindicated during breastfeeding. |
| Lactation Rating |
■ FDA Black Box Warning
None.
| Serious Effects |
Hypersensitivity to ergot alkaloidsPregnancyLactationSevere peripheral vascular diseaseCoronary artery diseaseHypertensionHepatic or renal impairment
| Precautions | May cause hypotension, bradycardia, or arrhythmias, especially with parenteral use., Use with caution in cardiovascular disease, hepatic impairment, or renal insufficiency., May exacerbate psychosis or confusional states in elderly patients., Avoid concurrent use with vasoconstrictors (e.g., ergot derivatives, triptans) due to risk of severe hypertension. |
| Food/Dietary | Avoid grapefruit juice as it may increase drug levels and risk of side effects. No other significant food interactions. Limit alcohol to prevent additive hypotensive effects. |
Loading safety data…
| L5 (Contraindicated) |
| Teratogenic Risk | Category X. Contraindicated in pregnancy due to ergot alkaloid-mediated uterine hypertonicity, placental insufficiency, and potential fetal hypoxia. First trimester: risk of spontaneous abortion. Second/third trimesters: fetal growth restriction, preterm labor, neonatal ergotism (convulsions, respiratory depression). |
| Fetal Monitoring | Monitor uterine activity, fetal heart rate, and maternal blood pressure. Discontinue immediately if signs of uterine hypertonicity or fetal distress. Avoid use in pregnancy; no routine monitoring recommended due to contraindication. |
| Fertility Effects | May impair fertility by inhibiting prolactin secretion, leading to anovulation and luteal phase defects. Reversible upon discontinuation. |
| Clinical Pearls | Hydergine LC (ergoloid mesylates) is a cognitive enhancer historically used for dementia, but its efficacy is marginal and it is not first-line. Monitor for orthostatic hypotension, especially in elderly. May take 4-6 weeks to see benefit; discontinue if no response. Avoid in patients with psychosis or severe bradycardia. |
| Patient Advice | Take exactly as prescribed; do not exceed dose. · May cause dizziness or low blood pressure when standing up; rise slowly. · Report any slow heart rate, fainting, or hallucinations. · It may take several weeks to notice improvement; continue medication as directed. · Avoid alcohol and grapefruit juice while taking this medication. |